Premium
New trials suggest no significant benefit from adjunctive aspirin for schizophrenia
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30704
Subject(s) - aspirin , positive and negative syndrome scale , schizophrenia (object oriented programming) , medicine , placebo , adjunctive treatment , randomized controlled trial , meta analysis , negative symptom , psychiatry , psychosis , alternative medicine , pathology
Two new randomized, placebo‐controlled trials have found no significant improvement in symptoms of schizophrenia resulting from use of adjunctive aspirin. The studies were included in a meta‐analysis that found a small but not statistically significant effect of aspirin on scores on the Positive and Negative Syndrome Scale (PANSS).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom